Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study

Louisa Maria Bulirsch,1 Marlene Saßmannshausen,1 Jennifer Nadal,2 Raffael Liegl,1 Sarah Thiele,1, Frank G Holz1

1Department of Ophthalmology, University of Bonn, Bonn, Germany; 2Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany

ABSTRACT

Background Brolucizumab has recently been approved in Europe as a novel treatment for patients with neovascular age-related macular degeneration (nAMD). We report on early experiences with real-world outcomes of switch to brolucizumab therapy in previously anti-vascular endothelial growth factor (anti-VEGF)-treated patients.

Methods Patients with recalcitrant nAMD were switched to brolucizumab therapy. Functional and structural parameters 4 weeks after first brolucizumab injection were evaluated including best-corrected visual acuity (BCVA (logMAR)), foveal centre point (FCP (µm)), central subfield retinal thickness (CSRT (µm)) and macular volume (mm³).

Results Sixty-three eyes of 57 patients with nAMD (52.6% females) with a mean (±SD) age of 79.5±6.7 years were included. Mean change of BCVA was 0.03±0.14 logMAR (p=0.115). Significant reductions were recorded for FCP with a mean (±SD) change of −66.81±72.63 µm, −66.76±60.71 µm for CSRT and −0.27±0.24 mm³ for macular volume (all p<0.001). Intraocular inflammation was observed in seven eyes of seven patients, including one case of retinal vasculitis.

Conclusions The results of the SHIFT study indicate that switch to brolucizumab may represent a treatment option in patients with nAMD poorly responsive to other anti-VEGF agents. Further long-term analyses appear prudent to assess efficacy and safety of brolucizumab in a routine clinical setting.

INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in industrialised countries.1 With the advent of anti-vascular endothelial growth factor (VEGF) therapy, the visual outcome of patients with neovascular AMD (nAMD) has been improved and measurable reductions of legal blindness incidence have emerged.2-3

Besides the anticipated worldwide increase of AMD prevalence due to demographical changes with longer life expectancy, the burden for both patients and caregivers is high when managing patients with repetitive intravitreal injections and monitoring visits over a long period of time in a chronic disease. Various real-world studies have shown visual outcomes to be inferior compared with the results from prospective randomised clinical trials (RCTs).4 Undertreatment is one of the major factors in part driven by non-adherence. In addition, some patients and certain subphenotypes of nAMD do not respond favourably.5-12 Therefore, more efficacious agents with longer durability represent an important unmet need.

Brolucizumab (Novartis), a single-chain antibody fragment, was recently approved for the treatment of nAMD in October 2019 and in February 2020 by the regulatory agencies in the USA and the European Union, respectively, as well as in other countries.13 Potential benefits of brolucizumab are assumed to be related to its low molecular weight with subsequent better tissue penetration as well as higher molar concentration.13-15 Two pivotal trials have recently shown non-inferiority of brolucizumab to the comparator aflibercept with regard to visual outcome.13 Post hoc analyses demonstrated overall favourable anatomical effects.16-18 However, safety signals have been reported in both RCTs and post-marketing reports, which included the occurrence of intraocular inflammation (IOI) and retinal vasculitis with or without occlusion.13-18-23

The aim of the SHIFT study was to report early real-world experiences in a single European clinical centre of brolucizumab treatment for nAMD with regard to both functional and anatomical disease control as well as adverse effects following approval in February 2020 in Europe.

METHODS

The SHIFT study is a retrospective, observational, monocentre study of patients with exudative AMD who received 6 mg brolucizumab intravitreal therapy between 16 March 2020 and 15 October 2020, at the Department of Ophthalmology, University of Bonn, Germany, in routine clinical care. All patients were previously treated repetitively because of recalcitrant fluid accumulations on optical coherence tomography (OCT) despite frequent dosing with other anti-VEGF agents, including ranibizumab, aflibercept and bevacizumab. Recalcitrant fluid was defined as persistent fluid accumulations despite a high frequency of intravitreal injections of other anti-VEGF agents over a longer period of time prior to the switch to brolucizumab. The day of the first intravitreal brolucizumab injection was regarded as the baseline visit.

At each visit, best-corrected visual acuity (BCVA) determination and complete ophthalmic examination, including slit-lamp examination and funduscopy following pupil dilation, was performed. Signs of IOI and/or retinal vasculitis were recorded if present. Retinal imaging was performed at each visit with combined confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography (SD-OCT) (Spectralis HRA2+OCT,
Heidelberg Engineering, Heidelberg, Germany) with acquisition of central 30°×30° near-infrared reflectance (λ=820 nm, ART (automatic real time) at least 15 frames). SD-OCT volume raster scans consisted of at least 19 B-scans (distance between neighbouring B-scans ≤240 μm) and a field size of at least 20°×15° (centred to the fovea) and included at least 5 frames (ART mode).

**Assessment of structural outcomes**
Morphological effects were quantified to assess structural efficacy of brolucizumab. Three parameters were determined: foveal centre point (FCP), defined as the distance (μm) between the internal limiting membrane (ILM) and Bruch’s membrane (BM); central subfield retinal thickness (CSRT), defined as the mean retinal thickness (μm) between ILM and BM of the circular area within 1 mm diameter around the centre of the fovea; as well as macular volume, defined as the mean volume of the retina in a circular area within 3 mm diameter around the fovea. For thickness and volume quantification, the automated segmentation of the Heidelberg Eye Explorer software V.2 (Heidelberg Engineering, V.2.4.1, Heidelberg, Germany) was carefully reviewed and, if indicated, manually corrected in each B-scan. Furthermore, a thorough evaluation of fluid distribution within the retina was performed with qualitative assessment of presence of subretinal, intraretinal and/or subretinal pigment epithelial (sub-RPE) fluid.

**Statistical analysis**
Statistical analysis was performed using SPSS (IBM SPSS Statistics V.25). The baseline characteristics are summarised by mean±SD and range (minimum–maximum) for normally distributed continuous variables.

BCVA was measured in decimals and for the purpose of this analysis converted to the logarithm of the minimum angle of resolution (logMAR).26-28

Functional and structural outcomes were determined at baseline and at first visit after switch to brolucizumab (visit 1). The outcomes were differences for each functional (logMAR) and structural (FCP, CSRT and macular volume) parameter between visit 1 and baseline. Descriptive values of these outcomes are shown with mean±SD and (95% CI). Linear mixed-effects models with the change of functional or structural parameter as the response variable were used to analyse the effects of treatment with brolucizumab. To account for dependencies between measurements from the same patient, patient-specific random intercepts and slopes (analysis of longitudinal data) were included in the mixed-effects models, P values smaller than 0.05 were considered significant.

**RESULTS**

**Study cohort**
Between 16 March 2020 and 15 October 2020, a total of 207 brolucizumab injections were performed with a mean (±SD) of 3.09±1.55 (range 1–7) brolucizumab injections per eye. Thirty-three eyes of 57 patients (30 females, 52.6%) with a mean (±SD) age of 79.5±6.7 (58–94) years were treated with at least one brolucizumab intravitreal injection (baseline) and were further assessed at the first visit after brolucizumab injection (visit 1) after a mean of 4.3±0.8 weeks (2.9–7.7). Table 1 summarises the results of descriptive analysis of the study cohort.

During the entire observation period, patients treated with brolucizumab were seen across a mean follow-up of 16.04±6.86 (2.86–27.43) weeks. All patients had received other anti-VEGF agents before switching to brolucizumab. Treatment history comprised a mean of 32.5±25.6 (3–126) anti-VEGF injections per eye over a mean period of 4.2±3.3 (0.3–13.4) years.

**Table 1** Study cohort characteristics at baseline (BSL) and visit 1 (V1)

<table>
<thead>
<tr>
<th>Per patient</th>
<th>BSL</th>
<th>V1</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=57</td>
<td>n=63</td>
<td></td>
</tr>
<tr>
<td>Age (years) (mean±SD)</td>
<td>79.4±6.65</td>
<td>58–94</td>
</tr>
<tr>
<td>Gender, female (n (%))</td>
<td>30</td>
<td>52.6</td>
</tr>
<tr>
<td>BCVA (logMAR)</td>
<td>0.39±0.28</td>
<td>0–1.2</td>
</tr>
<tr>
<td>FCP (μm)</td>
<td>363.32±133.03</td>
<td>89–826</td>
</tr>
<tr>
<td>CSRT (μm)</td>
<td>409.43±112.32</td>
<td>224–784</td>
</tr>
<tr>
<td>Macular volume (mm³)</td>
<td>2.72±0.51</td>
<td>2.07–4.63</td>
</tr>
</tbody>
</table>

BCVA, best-corrected visual acuity; CSRT, central subfield retinal thickness; FCP, foveal centre point.

**Functional outcome**
Mean BCVA was 0.39±0.28 (0–1.2) logMAR at baseline. After switch to brolucizumab, a mean change in visual acuity of 0.03±0.14 (95% CI −0.01; 0.06) logMAR was detected at visit 1 (p=0.115). See table 1 for absolute values at baseline and visit 1 and table 2 for the change of functional outcome under brolucizumab treatment. A graphical outcome representation is provided in figure 1.

**Anatomical outcomes**
Regarding structural quantitative parameters, mean (±SD) FCP was 363.32±133.03 (89–826) μm, mean CSRT was 409.43±112.32 (224–784) μm and mean macular volume was 2.72±0.51 (2.07–4.63) mm³ at baseline. At visit 1, mean change in FCP was −66.81±72.63 (−85.1; −48.5) μm, in CSRT −66.76±60.71 (−82.05; −51.47) μm and in macular volume −0.27±0.24 (−0.33; −0.2) mm³ (all: p<0.001). See table 1 for absolute values at baseline and visit one and table 2 for the changes of structural parameters under brolucizumab treatment. A graphical representation of the outcomes is provided in figure 1.

**Assessment of qualitative SD-OCT parameters**
For the following analysis, two eyes of two patients with frequent previous injections but without intraretinal, subretinal fluid or sub-RPE fluid at baseline were excluded. Thirty-one eyes (96.8%) of 55 patients presented at baseline with intraretinal and/or subretinal and/or sub-RPE fluid (eyes with intraretinal, intraretinal and sub-RPE fluid: n=7; eyes with only subretinal and intraretinal fluid: n=4; eyes with subretinal and sub-RPE fluid: n=18; eyes with intraretinal and sub-RPE fluid: n=6; eyes with only subretinal fluid: n=13; eyes with only intraretinal fluid: n=12; eyes with only sub-RPE fluid: n=1) detected by SD-OCT imaging. At visit 1, absence of fluid in any retinal compartment was detected in 18 eyes (29.5%) of 18 patients.

At baseline, 27 eyes of 27 patients demonstrated (with or without fluid in any other compartment) intraretinal and 42 eyes of 38 patients demonstrated subretinal fluid, respectively. After initiation of brolucizumab treatment (visit 1), 11 eyes (40.7%) of 11 patients with intraretinal and 24 eyes (57.1%) of 21 patients with subretinal fluid at baseline showed complete resolution. Out of the 30 eyes of 27 patients demonstrating sub-RPE fluid at baseline, complete sub-RPE fluid resolution at visit...
1 was detectable in only 6 eyes (20%) of 6 patients. For exemplary cases of structural response to brolucizumab treatment, see figures 2–5.

Adverse events
During the observation period, adverse events were reported in eight eyes (12.7%) of eight patients. In one patient, a vitreous haemorrhage occurred immediately following the intravitreal injection, which was considered as a procedure-related and not drug-related event. Vitreous haemorrhage resolved spontaneously and required no further therapeutic intervention.

Out of the 63 eyes of 57 patients treated with brolucizumab, 7 eyes (11.1%) of 7 patients (3.38% per 207 given injections) with a mean age of 80.7±9.1 years (4 females, 57.1%) developed various degrees of IOI, which was suspected to be drug related. Out of the seven eyes with IOI, anterior uveitis with anterior chamber cells only was noted in two patients. Four eyes had additional signs of intermediate uveitis with occurrence of anterior and vitreous cells. In one patient, segmental periarteriolar sheathing was noted without concurrent retinal vascular occlusion (figure 6). Due to IOI development, four patients sought medical attention at an unscheduled visit, while three patients presented at a regularly scheduled visit. Once signs of IOI development were detected, treatment with brolucizumab for nAMD was discontinued and patients were switched back to an alternate anti-VEGF drug.

Regarding the time of IOI development, four patients developed signs of IOI after the first brolucizumab injection with occurrence of first symptoms after a mean of 19.0±6.5 (12–25) days. Medical attention was sought after a mean of 23.8±6.4 (13–29) days after injection. In the three patients with IOI development after the second brolucizumab injection, first symptoms occurred after a mean of 7.3±5.6 (2–15) days. Medical advice was sought after 8.7±5.2 (5–16) days. During the observation period, no patient receiving at least three brolucizumab injections developed any signs of IOI.

Initial symptoms differed between the patients with IOI development. Eye redness as the initial symptom was reported by four patients, while three reported floaters and/or cloudy vision. One patient reported a decrease in visual acuity. None of the patients with documented adverse events reported earlier episodes of uveitis or ocular autoimmune disease, except for one patient

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Mean±SD</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change BCVA (logMAR)</td>
<td>0.03±0.14</td>
<td>(−0.01 to 0.06)</td>
<td>0.115</td>
</tr>
<tr>
<td>Change FCP (µm)</td>
<td>−66.81±72.63</td>
<td>(−85.10 to −48.52)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Change CSRT (µm)</td>
<td>−66.76±60.71</td>
<td>(−82.05 to −51.47)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Change macular volume (mm³)</td>
<td>−0.27±0.24</td>
<td>(−0.33 to −0.20)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 2  Functional and structural outcomes after switch to brolucizumab

BCVA, best-corrected visual acuity; CSRT, central subfield retinal thickness; FCP, foveal centre point.

Figure 1  Boxplots (each box: median; 75% and 25% quartiles; whiskers: 10% and 90% quantiles; outliers are defined as sample outliers 1.5 times (circles) and 3 times (star) the IQR above the upper quartile and below the lower quartile) at baseline (BSL) and visit 1 (V1) for (A) best-corrected visual acuity (BCVA (logMAR)), (B) focal centre point (FCP (µm)), (C) central subfield retinal thickness (CSRT (µm)) and (D) macular volume (mm³). Structural outcomes (B–D) showed a significant change after brolucizumab treatment.
who had a history of bilateral macular oedema interpreted as Irvine-Gass syndrome following routine cataract surgery with intraocular lens implantation.

Treatment was initiated promptly according to the severity of the documented IOI. In cases with only mild IOI and without signs of posterior uveitis or vasculitis, topical therapy with corticosteroid eye drops (dexamethasone or prednisolone) was initiated with application ranging from four times a day up to every hour and ointment (prednisolone) before hours of sleep. In four patients, topical therapy was supplemented by a subconjunctival injection of dexamethasone (8 mg). In the single patients who presented with vasculitis and in three patients with more severe IOI, additional systemic therapy with corticosteroids was initiated in a body weight adapted dose (ie, 60 or 80 mg) and subsequently tapered off according to IOI activity. None of the seven patients demonstrated persistent clinical relevant change in visual acuity once IOI had ceased.

**DISCUSSION**

Efficacious therapy with maintaining visual acuity gains during the upload phase in the long-term management of patients with chronic nAMD still represents an unmet need. Recently, brolucizumab was approved as a new anti-VEGF agent for intravitreal administration in patients with nAMD. However, only limited data of its use in a real-world setting are available to date.16 17 20–22

Herein, we report early experiences with brolucizumab use in clinical routine in a single centre in Europe following approval in February 2020 (SHIFT study). Our findings indicate that initiation of intravitreal brolucizumab therapy in previously treated patients with nAMD (switch) may be an option in particular with regard to the morphological effects in recalcitrant cases who previously received multiple anti-VEGF injections without satisfactory resolution of fluid in various anatomical compartments. A significant reduction on average of retinal thickness parameters, including FCP, CSRT and macular volume, was observed demonstrating a favourable response on morphological signs for disease activity. Although differences in study design and analysis methods limit a direct comparison, our findings mirror a recent real-world report by Sharma et al, who also showed improvement in structural outcomes in 42 eyes of 42 patients with nAMD over a mean (±SD) observational period of 7.2±3.6 weeks.16 In accordance with our study, Avaylon and colleagues have also found beneficial structural outcomes at first visit following switch to brolucizumab.21 Although the analysis of this

---

**Figure 2** Exemplary case of a patient with subretinal fluid at baseline (BSL) (D) and both intraretinal and subretinal fluid 1 (C), 3 (B) and 6 (A) months in historical imaging before baseline despite regular anti-vascular endothelial growth factor (anti-VEGF) treatment as demonstrated in (from left to right) near-infrared imaging, spectral-domain optical coherence tomography through the fovea and colour-coded two-dimensional thickness map for total retinal thickness. One month after switch to brolucizumab (E, visit 1), complete resolution of subretinal fluid was detected. Note: Before switch to brolucizumab, the patient received repetitive, high-frequency intravitreal injections of other anti-VEGF agents over a longer period of time.

**Figure 3** Exemplary case of a patient with subretinal pigment epithelial (sub-RPE) fluid at baseline (BSL) (D) and in historical imaging up to 11 months (A–C) before switch to brolucizumab as demonstrated in (from left to right) near-infrared imaging, spectral-domain optical coherence tomography through the fovea and colour-coded two-dimensional thickness map for total retinal thickness. At visit 1 (E), complete resolution of sub-RPE fluid was detected. Note: Before switch to brolucizumab, the patient received repetitive, high-frequency intravitreal injections of other anti-vascular endothelial growth factor agents over a longer period of time.
Standing ocular history of exudative AMD in our cohort, under-
been observed before in other switch studies. Given the long-
defined efficacy outcome parameters. This phenomenon has
of BCVA improvement despite significant change in structurally
azumab of 0.39±0.28 logMAR but may also explain the lack
13–19 21–23 31 The pathogenesis of the inflamma-
tion of anterior chamber cells to retinal vasculitis with or without occlu-
formed two-dimensional thickness map for total retinal
thickness. Retinal imaging at visit 1 (E) revealed complete resolution of
subretinal and sub-RPE fluid. Note: Before switch to brolucizumab, the
patient received repetitive, high-frequency intravitreal injections of other
anti-vascular endothelial growth factor agents over a longer period of
time.

Figure 4 Exemplary case of a patient with subretinal pigment
epithelial (sub-RPE) and subretinal fluid at baseline (BSL) (D) as
well as in historical imaging up to 8 months (A–C) before switch to
brolucizumab as demonstrated in (from left to right) near-infrared
imaging, spectral-domain optical coherence tomography through the
fovea and colour-coded two-dimensional thickness map for total retinal
thickness. Retinal imaging at visit 1 (E) revealed complete resolution of
subretinal and sub-RPE fluid. Note: Before switch to brolucizumab, the
patient received repetitive, high-frequency intravitreal injections of other
anti-vascular endothelial growth factor agents over a longer period of
time.

Figure 5 Exemplary case of a patient with intraretinal and subretinal
fluid at baseline (BSL) (D) and in historical images 1 (C), 2 (B) and 6
(A) months before switch to brolucizumab as demonstrated in (from
left to right) near-infrared imaging, spectral-domain optical coherence
tomography through the fovea and colour-coded two-dimensional
thickness map for total retinal thickness. One month after switch (E,
visit 1), complete resolution of subretinal and incomplete resolution
of intraretinal fluid was demonstrated. Note: Before switch to
brolucizumab, the patient received repetitive, high-frequency intravitreal
injections of other anti-vascular endothelial growth factor agents over a
longer period of time.

group is based on a rather small cohort of only six patients, our
results confirm the observations by Avaylon et al of improve-
ment of various OCT characteristics.

When interpreting the functional outcome in our study, it
needs to be considered that the SHIFT cohort comprises previ-
sely treated patients only, with up to 126 previous intravitreal
anti-VEGF injections (with a mean (±SD) of 32.5±25.6). This
might not only impact the BCVA before initial injection of brolu-
cizumab of 0.39±0.28 logMAR but may also explain the lack
of BCVA improvement despite significant change in structurally
defined efficacy outcome parameters. This phenomenon has
been observed before in other switch studies. Given the long-
standing ocular history of exudative AMD in our cohort, under-
lying structural, in part irreversible damage may contribute to
a limited potential of visual recovery. 26–32 The phenomenon of
disconnect between morphology and function has been observed in
other switch studies of patients with nAMD. 26–32

Since the approval of brolucizumab, safety signals of devel-
opment of IOI following brolucizumab treatment, ranging from
anterior chamber cells to retinal vasculitis with or without occlu-
and with or without moderate and severe visual loss, have
been reported. 13 19 21–23 31 The pathogenesis of the inflamma-
tory events is not yet understood and needs further investiga-
tions which are ongoing. In the pivotal phase-III HAWK and
HARRIER studies of treatment-naive nAMD patients, an overall
rate of 4.6% of any IOI was reported following a review by a
safety review committee (SRC). 34 The rate of the development of
retinal vasculitis was reported to be 3.3% (36/1088) and that
of concomitant retinal vasculitis and retinal vascular occlusion
was 2.1% (23/1088), respectively. 13 The overall incidence of at
least moderate vision loss due to IOI was <1%. Recently, the
American Society of Retina Specialists referred to post approval,
reported IOI cases that the majority (88%) was of female gender
in accordance with other published reports of brolucizumab
cases. 18 20–22 In line with these previous reports, IOI occurred in
our small cohort more frequently in female patients, while the
case of retinal arteriolar vasculitis was detected in a male patient
who showed a favourable outcome in the absence of retinal
vascular occlusion and resolution of the intraocular inflamma-
tion following steroid therapy.

In the patients reported here, anti-inflammatory treatment
was initiated promptly following detection of IOI and included
topical, subconjunctival and systemic corticosteroid therapy.
In none of the patients functional deficits occurred following
IOI resolution. In the meantime, recommendations have been
published on the management of patients with nAMD who
develop IOI following brolucizumab treatment. 34

Various limitations need to be considered for this study. This is
an observational study in a relatively small cohort of 57 patients.
An important limitation of our study is the short review period
post switch to brolucizumab of 1 month. In this real-world study,
we applied a treat & extend scheme immediately after the first
injection and did not perform three fixed 4-weekly injections
post switch to brolucizumab as proposed in other switch studies.
Therefore, in this relatively small cohort, data analyses beyond
1 month would be based on a variable number of injections after
switch and would not allow a meaningful analysis and compar-
ison between patients. Accordingly, the same applies to an
analysis of the treatment history before switch to brolucizumab. Furthermore, no treatment-naïve patients were investigated compromising any overall conclusion on structural and visual outcome following treatment. Finally, the study cannot address the questions of potentially longer durability of brolucizumab compared with other anti-VEGF agents in particular during a treat & extend regimen. To determine this, both longitudinal assessments in real-world settings and randomised clinical nAMD trials are warranted.

In summary, the SHIFT study reports real-world early experiences outside RCTs with brolucizumab in previously anti-VEGF-treated patients with nAMD. A beneficial morphological effect was recorded pointing towards a strong antihyperpermeability effect of this agent. Safety issues with regard to IOI remain a concern and require further investigations with regard to the underlying mechanisms as well as risk mitigation measures.

**Correction notice** This paper has been corrected since it was published online first.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** Non-financial support from Heidelberg Engineering to ST, LB, RL, MS and FGH; from CenterVue to ST and FGH; from Optos to ST, LB, RL, MS and FGH; from Carl Zeiss Meditec to ST, LB, RF, FGH and MS. Grant and personal fees from Allergan, Novartis, Bayer and Heidelberg Engineering to ST and FGH; from Apellis, Carl Zeiss Meditec, Acucela, Genentech/Roche, Boehringer-Ingelheim, LIN Bioscience, Pixium, Kanghong, Otsurion, Grayburd Vision, Stealth BioTherapeutics, Geuder and Ivenic Bio to FGH. JN: None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study does not contain personal information from any identifiable individual. Because this study is a retrospective analysis of data obtained in clinical routine care at an academic university setting, no ethics approval is required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to this study are included in the article.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD** Sarah Thiele http://orcid.org/0000-0002-1123-6700

**REFERENCES**

Clinical science


